The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome
Abstract
Delivery of targeted hematopoietic irradiation using radiolabeled monoclonal antibody may improve the outcome of marrow transplantation for advanced acute leukemia by decreasing relapse without increasing toxicity. We conducted a phase I study that examined the biodistribution of 131I-labeled anti-CD45 antibody and determined the toxicity of escalating doses of targeted radiation combined with 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI) followed by HLA-matched related allogeneic or autologous transplant. Forty-four patients with advanced acute leukemia or myelodysplasia received a biodistribution dose of 0.5 mg/kg131I-BC8 (murine anti-CD45) antibody. The mean ± SEM estimated radiation absorbed dose (centigray per millicurie of 131I) delivered to bone marrow and spleen was 6.5 ± 0.5 and 13.5 ± 1.3, respectively, with liver, lung, kidney, and total body receiving lower amounts of 2.8 ± 0.2, 1.8 ± 0.1, 0.6 ± 0.04, and 0.4 ± 0.02, respectively. Thirty-seven patients (84%) had favorable biodistribution of antibody, with a higher estimated radiation absorbed dose to marrow and spleen than to normal organs. Thirty-four patients received a therapeutic dose of 131I-antibody labeled with 76 to 612 mCi131I to deliver estimated radiation absorbed doses to liver (normal organ receiving the highest dose) of 3.5 Gy (level 1) to 12.25 Gy (level 6) in addition to CY and TBI. The maximum tolerated dose was level 5 (delivering 10.5 Gy to liver), with grade III/IV mucositis in 2 of 2 patients treated at level 6. Of 25 treated patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 7 survive disease-free 15 to 89 months (median, 65 months) posttransplant. Of 9 treated patients with acute lymphoblastic leukemia (ALL), 3 survive disease-free 19, 54, and 66 months posttransplant. We conclude that 131I-anti-CD45 antibody can safely deliver substantial supplemental doses of radiation to bone marrow (∼24 Gy) and spleen (∼50 Gy) when combined with conventional CY/TBI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Farewell, V., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citationRegimen-related toxicity in patients undergoing bone marrow transplantation.
Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Petersen, F. B., Fisher, L. D., Clift, R. A., & Thomas, E. D. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1562 · Cited by 868
Self-citationSpecific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn
Cristy, M., & Eckerman, K. F. (1987) · doi:10.2172/6202949 · Cited by 692
Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support
Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310213291702 · Cited by 644
Self-citationClift, R., Buckner, C., Appelbaum, F., Bearman, S., Petersen, F., Fisher, L., Anasetti, C., Beatty, P., Bensinger, W., & Doney, K. (1990) · Blood · doi:10.1182/blood.v76.9.1867.1867 · Cited by 585
Self-citationMIRD primer for absorbed dose calculations
LOEVINGER, R., Budinger, T. F., & Watson, E. E. (1988) · Medical Entomology and Zoology · Cited by 552
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
MIRDOSE: Personal Computer Software for Internal Dose Assessment in Nuclear Medicine
Piwnica-Worms, D. (1996) · Cited by 500
Yeager, A. M., Kaizer, H., Santos, G. W., Saral, R., Colvin, O. M., Stuart, R. K., Braine, H. G., Burke, P. J., Ambinder, R. F., Burns, W. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607173150301 · Cited by 431
Press, O. W., Appelbaum, F., Martin, P. J., Matthews, D. C., Bernstein, I. D., Eary, J. F., Nelp, W. B., Gooley, T., Glenn, S., Porter, B., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92225-3 · Cited by 428
Self-citationMIRD Primer for Absorbed Dose Calculations
Malamud, H. (1989) · Clinical Nuclear Medicine · doi:10.1097/00003072-198909000-00027 · Cited by 326
Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.
Knox, S. J., Goris, M. L., Trisler, K. D., Negrin, R. S., Davis, T., Liles, T. M., Grillo-López, A. J., Chinn, P. C., Varns, C., Ning, S., et al. (1996) · PubMed · Cited by 326
Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
Sgouros, G. (1993) · PubMed · Cited by 303
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., & Krohn, K. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1027 · Cited by 274
Self-citationWaldmann, T., White, J., Carrasquillo, J., Reynolds, J., Paik, C., Gansow, O., Brechbiel, M., Jaffe, E., Fleisher, T., & Goldman, C. (1995) · Blood · doi:10.1182/blood.v86.11.4063.bloodjournal86114063 · Cited by 249
Scheinberg, D. A., Lovett, D., Divgi, C. R., Graham, M. C., Berman, E., Pentlow, K., Feirt, N., Finn, R. D., Clarkson, B. D., & Gee, T. S. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.478 · Cited by 224
Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., & Izon, D. O. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.548 · Cited by 199
Human homologue of murine T200 glycoprotein.
Omary, M. B., Trowbridge, I. S., & Battifora, H. A. (1980) · The Journal of experimental medicine · doi:10.1084/jem.152.4.842 · Cited by 189
Rosen, S. T., Zimmer, A. M., Goldman-Leikin, R., Gordon, L. I., Kazikiewicz, J. M., Kaplan, E. H., Variakojis, D., Marder, R. J., Dykewicz, M. S., & Piergies, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.562 · Cited by 180
Matthews, D., Appelbaum, F. R., Eary, J. F., Fisher, D., Durack, L. D., Bush, S. A., Hui, T., Martin, P., Mitchell, D., & Press, O. W. (1995) · Blood · doi:10.1182/blood.v85.4.1122.bloodjournal8541122 · Cited by 155
Self-citationDown, J. D., Tarbell, N. J., Thames, H. D., & Mauch, P. M. (1991) · Blood · doi:10.1182/blood.v77.3.661.661 · Cited by 122
Vriesendorp, H. M., Herpst, J., Germack, M. A., Klein, J., Leichner, P. K., Loudenslager, D. M., & Order, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.6.918 · Cited by 119
Imaging and treatment of B-cell lymphoma.
Eary, J. F., Press, O. W., Badger, C. C., Durack, L. D., Richter, K. Y., Addison, S. J., Krohn, K. A., Fisher, D. R., Porter, B. A., & Williams, D. L. (1990) · PubMed · Cited by 112
Self-citationFractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
DeNardo, G. L., DeNardo, S. J., O'Grady, L. F., Lévy, N., Adams, G. P., & Mills, S. L. (1990) · PubMed · Cited by 110
The Multichain Interleukin-2 Receptor: A Target for Immunotherapy
Waldmann, T. A., Pastan, I. H., Gansow, O. A., & Junghans, R. P. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-2-148 · Cited by 97
Scheinberg, D. A., Straus, D. J., Yeh, S.-D., Divgi, C. R., Garin‐Chesa, P., Graham, M. C., Pentlow, K. S., Coit, D. G., Oettgen, H. F., & Old, L. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.792 · Cited by 89
Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
Huneke, R. B., Pippin, C. G., Squire, R. A., Brechbiel, M. W., Gansow, O. A., & Strand, M. (1992) · PubMed · Cited by 86
Determinants of the antitumor effect of radiolabeled monoclonal antibodies.
Knox, S. J., Levy, R., Miller, R., Uhland, W., Schiele, J., Ruehl, W. W., Finston, R. A., Day-Lollini, P. A., & Goris, M. L. (1990) · PubMed · Cited by 85
Buchsbaum, D. J., Wahl, R. L., Normolle, D. P., & Kaminski, M. S. (1992) · PubMed · Cited by 84
Radiolabeled anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque
Matthews, D., Appelbaum, F. R., Eary, J. F., Hui, T., Fisher, D., Martin, P., Durack, L. D., Nelp, W., Press, O. W., & Badger, C. C. (1991) · Blood · doi:10.1182/blood.v78.7.1864.1864 · Cited by 70
Self-citationPloemacher, R., van Os, R. P., Beurden, C. A. J. V. D. L.-V., & Down, J. D. (1992) · International Journal of Radiation Biology · doi:10.1080/09553009214551251 · Cited by 67
Macklis, R. M., Beresford, B. A., Palayoor, S. T., et al. (1993) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(93)90391-8 · Cited by 63
DeNardo, G. L., Lamborn, K. R., Goldstein, D. S., Kroger, L. A., & DeNardo, S. J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12+<2706::aid-cncr49>3.0.co;2-d · Cited by 62
Treatment of Lymphoma With Radiolabeled Antibody: Elimination of Tumor Cells Lacking Target Antigen
Nourigat, C., Badger, C. C., & Bernstein, I. D. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.47 · Cited by 57
Self-citationThe use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia
Ruble, G., Wu, C., Squire, R. A., Gansow, O. A., & Strand, M. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02119-1 · Cited by 49
Cited by
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
Self-citationConditioning regimens for hematopoietic cell transplantation: one size does not fit all
Gyurkocza, B., & Sandmaier, B. M. (2014) · Blood · doi:10.1182/blood-2014-02-514778 · Cited by 614
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
Self-citationTargeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Metadata
- Authors
- Matthews, D. C., Appelbaum, F. R., Eary, J. F., Fisher, D. R., Durack, L. D., Hui, T. E., Martin, P. J., Mitchell, D., Press, O. W., Storb, R., & Bernstein, I. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-08-15
- Volume
- 94
- Issue
- 4
- Pages
- 1237-1247
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1576593419
- Cited by
- 312
- References
- 35
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.